Abstracts tagged "osteoclastogenesis and treatment"

Abstract Number: 1038 • 2018 ACR/ARHP Annual Meeting
Tenofovir, a Nucleoside Analog Reverse Transcriptase Inhibitor for Treatment of HIV, Promotes Osteoclast Differentiation and Decreases Osteoblast Formation By a Mechanism Depending on ATP Release and Adenosine
Francisco Miguel Conesa-Buendia¹, Patricia Llamas², Raquel Largo³, Gabriel Herrero-Beaumont³, Bruce N. Cronstein⁴ and Aranzazu Mediero⁵, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz- UAM, Madrid, Spain, ²Bone and Joint Research Unit, IIS-Fundacion Jimenez Díaz-UAM, Madrid, Spain, ³Bone and Joint Research Unit, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁴Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ⁵Joint and Bone Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Human Immunodeficiency Virus (HIV) infection devastates the immune system but also affects tissues and organs such as kidney, liver, central nervous system, heart and…
Abstract Number: 2089 • 2015 ACR/ARHP Annual Meeting
Netrin-1 and Its Receptors Unc5b and DCC May be Useful Targets for Preventing Multiple Myeloma Bone Lesions
Aranzazu Mediero¹, Tuere Wilder² and Bruce Cronstein³, ¹Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, ²Dept of Med, Div of Rheum, NYU School of Medicine, New York, NY, ³Medicine, Division of Rheumatology, NYU School of Medicine, NEW YORK, NY
Background/Purpose: Multiple Myeloma is characterized by the uncontrolled proliferation of plasma cells. This type of malignancy is particularly trophic to bone where it induces osteoclastic…
Abstract Number: 3190 • 2015 ACR/ARHP Annual Meeting
Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis
Aranzazu Mediero¹, Tuere Wilder² and Bruce Cronstein³, ¹Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, ²Dept of Med, Div of Rheum, NYU School of Medicine, New York, NY, ³Medicine, Division of Rheumatology, NYU School of Medicine, NEW YORK, NY
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and destruction of the joints and some extra-articular tissues. Netrin-1 is a laminin-like…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].